Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG - with promising results identified.

Artist's impression of the rabies virus

The RAB001 trial was conducted at the University and is the first time the novel rabies vaccine has been used in human volunteers. The aim of the study was to look at safety and measure immune responses from the vaccine by analysing levels of rabies neutralising antibodies – a powerful marker of successful rabies vaccination.

In their findings (published in The Lancet Microbe), the researchers reported that 12 volunteers were recruited into the study in total, with three receiving a low dose, three receiving a medium dose and six receiving a high dose of ChAdOx2 RabG. Strong immune responses against rabies were generated by the vaccine, with all volunteers who received a medium or high dose developing levels of rabies neutralising antibodies above the World Health Organisation protective threshold (0.5 International Units / ml) within two months.

Read the full story on the University of Oxford website

Similar stories

Tackling suicide risk in people with mental disorders

Clinical researchers from Oxford University’s Department of Psychiatry and Oxford Health NHS Foundation Trust, together with colleagues from elsewhere, have developed guidance to help clinicians identify and treat patients at risk of suicide.

Environmental impact of 57,000 multi-ingredient processed foods revealed

A study estimating the environmental impact of 57,000 food products in the UK and Ireland has been published by an Oxford-led research team in the journal PNAS.

Oxford spinout MiroBio acquired by Gilead Sciences for $405m

The inflammatory diseases company’s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.

DPAG hosts successful first Science in the Park event

More than 100 children, along with around 50 parents, grandparents and caregivers enjoyed an exciting variety of activities on the theme of ‘How the Body Works’ in University Parks on Tuesday 26 July. This ‘Science in the Park’ event was run by the Department of Physiology, Anatomy & Genetics (DPAG) Outreach and Public Engagement Working Group (OPEWG) and volunteers comprising research scientists, clinical anatomy teaching staff, and graduate and undergraduate students.

Viral role in Alzheimer's Disease discovered

Researchers from Oxford’s Institute of Population Ageing, Tufts University and the University of Manchester have discovered that common viruses appear to play a role in some cases of Alzheimer’s disease (AD).